Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07498426 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 42 → 64 locations
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 7 of 11 entries
  2. Trial sites expanded: 24 → 42 locationsv8
  3. Trial sites expanded: 19 → 24 locations
    • Trial sites expanded: 6 → 19 locations
    v7
  4. Study sites: 6 to 19
    • Start date changed from estimate of May 29, 2026 to Jun 3, 2026
    v6
  5. Trial sites expanded: 3 → 6 locationsv5
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 2 to 3v4
  2. Study sites: 1 to 2v3
  1. Recruitment opened
    • Study sites: 0 to 1
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 34 trials at risk
This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP). Eligible participants will be randomized to receive either NIO752 or placebo followed by an open-label extension.
Trial Details
NCT Number NCT07498426
Lead Sponsor Novartis Pharmaceuticals
Conditions
(from sponsor)		 Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Related terms Pick Disease of the Brain, Supranuclear Palsy, Progressive
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov